Novartis Inks $390M FCA Deal Over Pharmacy Discounts

Law360, New York (October 27, 2015, 11:13 AM EDT) -- Novartis AG on Tuesday said it has tentatively agreed to shell out $390 million to end a whistleblower's False Claims Act suit alleging improper kickbacks to pharmacies to boost sales of several prescription drugs.

With a trial looming next week, Novartis has agreed to pay up to end allegations that it provided improper discounts and rebates to specialty pharmacies. (Credit: AP) The case was joined in 2013 by the U.S. Department of Justice and was set for trial next week, raising the specter of billions of dollars in damages and penalties. On Tuesday, Novartis said it had reached a "settlement in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!